Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice

Microscopy Research and Technique

Volumn 52, Issue 6, 2001, Pages 731-739

  Onuki, Manabu ^a   Ayers, Margaret M ^b   Bernard, Claude C A ^a   Orian, Jacqueline M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Animal model; Axonal degeneration; Demyelination; Multiple sclerosis; Remyelination

Indexed keywords

MAMMALS; PATHOLOGY;

ANIMAL MODEL; AXONAL DAMAGE; AXONAL DEGENERATION; CENTRAL NERVOUS SYSTEMS; DEMYELINATION; INFLAMMATORY DISORDERS; MULTIPLE SCLEROSIS; OLIGODENDROCYTES; REMYELINATION; TISSUE DESTRUCTION;

IMMUNE SYSTEM;

MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; DEMYELINATION; DISEASE COURSE; ELECTRON MICROSCOPY; FEMALE; HISTOLOGY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REMISSION; REMYELINIZATION; REVIEW;

ANIMALIA; MURINAE;

EID: 0035869253     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.1057     Document Type: Review

References (28)

1. Adams CWM. 1983. The general pathology of multiple sclerosis: Morphological and chemical aspects of the lesion. In: Hallpike JF, Adams CWM, Tourtellote WW, editors. Multiple sclerosis: pathology, diagnosis and management, London: Chapman and Hall, 203-240.
2. Allen I, Brankin B. 1993. Pathogenesis of multiple sclerosis: the immune diathesis and the role of viruses. J Neuropathol Exp Neurol 52:95-105.
3. Amor S, Groame N, Linington C, Harris MM, Dormair K, Gardiner MV, Mattheiu JM, Baker D. 1994. Identification of eiptopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi mice AB/H. J Immunol 25:1951-1959.
4. Bernard CCA, Carnegie PR, Mackay IR. 1983. Immunoregulatory mechanisms in experimental autoimmune encephalomyelitis in multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellote WW, editors. Multiple sclerosis: pathology, diagnosis and management. Chapman and Hall eds., p 513-578.
5. Bernard CCA, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. 1997. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75:77-88.
6. Ferguson B, Matyszak MK, Esiri MM, Perry WH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
7. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S. 1998. A serial study of new lesions and the white matter from which they arise. Neurology 51:1689-1707.
8. Hunter SF, Rodriguez M. 1995. Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Springer Semin Immunopathol 17:89-105.
9. Johns TG, Kerlero de Rosbo N, Menon KK, Abo S, Gonzales MF, Bernard CCA. 1995. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 154:5536-5541.
10. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. 1997. Remyelination in multiple sclerosis. Multiple Sclerosis 3:133-136.
11. Noseworthy JH. 1999. Progress in determining the causes and treatment of multiple sclerosis. Nature 399 (Suppl):A40-A47.
12. Orian JM, Slavin A, Ayers M, Bernard CCA. 1997. Delayed and incomplete myelination in a transgenic mouse with abnormal oligodendrocytes. J Neurosci Res 50:809-820.
13. Prineas JW. 1985. The neuropathology of multiple sclerosis. In: Koetser JC, editor. Handbook of clinical neurology, vol. 3: demyelinating diseases. New York: Elsevier Science Publications, p 213-257.
14. Raine C. 1984. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50:608-635.
15. Raine CS. 1996. Multiple sclerosis: prospects for remyelination. Multiple Sclerosis 2:195-197.
16. Raine CS. 1997. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77:135-152.
17. Raine CS, Cross AH. 1989. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 60:714-725.
18. Scolding N, Franklin R. 1998. Axon loss in multiple sclerosis. Lancet 352:340-341.
19. Scolding N, Lassmann H. 1996. Demyelination and remyelination. Trends Neurol Sci 19:1-2.
20. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, Bernard CCA. 1998. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28:109-120.
21. Steinman L. 1996. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302.
22. Steinman L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511-514.
23. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner JM, Olsson T, Linington C, Lassman H. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694.
24. Swanborg RH. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Pathol 77:4-13.
25. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Lars B. 1998. Axonal transection in the lesion of multiple sclerosis. New Engl J Med 5:278-285.
26. Trapp BD, Ranshoff RM, Fisher E, Rudick RA. 1999. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5:48-57.
27. Waxman SG. 1998. Demyelinating diseases: new pathological insights, new therapeutic targets. New Engl J Med 338:323-325.
28. Witt A, Brady ST. 2000. Unwrapping new layers of complexity in axon/glial relationships. Glia 29:112-117.